Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
P Galván, Yu Xia(Wenzhou Medical University), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Denzil Garteiz-Martínez, Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Judit Matito(Oryzon Genomics (Spain)), Meritxell Bellet(Vall d'Hebron Hospital Universitari), C Saura, C.M. Perou(University of North Carolina at Chapel Hill), Anna Suñol(Universitat Autònoma de Barcelona), Mariana M.S. Oliveira, Marina Gómez-Rey(Vall d'Hebron Institute of Oncology), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), B. Gonzalez-Farre, Olga Martínez‐Sáez(Breast Cancer Research Foundation), Esther Sanfeliu(Hospital Clínic de Barcelona), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ester Ballana(Universitat Autònoma de Barcelona), A. Vivancos, Núria Chic(Breast Cancer Research Foundation), Eva Ciruelos(Hospital Universitario 12 De Octubre), Patricia Villagrasa, Mercedes Marín‐Aguilera(Oryzon Genomics (Spain)), A. Prat(Target (United States)), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), J.S Parker(University of North Carolina at Chapel Hill), Enriqueta Felip(Institut Català d'Ornitologia), María Vidal(Inserm), A Rodríguez, Bárbara Adamo(Hospital Clínic de Barcelona)
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
May 17, 2024
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k